US EditionPositive Phase 2 Results on NBI-1117568 for Schizophrenia Presented at 2025 ASCP Annual Meeting
- Neurocrine Biosciences shared encouraging Phase 2 results involving NBI-1117568 in a clinical trial conducted on adult patients diagnosed with schizophrenia at the 2025 American Society of Clinical Psychopharmacology meeting held in Scottsdale, Arizona.
- This study arose from the ongoing need for effective, tolerable schizophrenia treatments, as traditional antipsychotics often cause adverse effects and therapy discontinuation.
- The randomized, double-blind, placebo-controlled, dose-finding Phase 2 trial included 210 adults aged 18 to 55, testing multiple NBI-1117568 doses over six weeks with a two-week safety follow-up.
- The study showed statistically significant symptom improvement on the PANSS total score by Week 3 at 20 mg once daily, with NBI-1117568 generally safe and well tolerated despite higher somnolence versus placebo .
- Based on positive Phase 2 results, Neurocrine Biosciences initiated a global, double-blind Phase 3 trial expecting 280 patients to further evaluate NBI-1117568’s efficacy, safety, and tolerability.
13 Articles
13 Articles
Missoulian
Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
SAN DIEGO, May 28, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the presentation of data from the Phase 2 study of NBI-1117568 in adults with schizophrenia, which showed a significant improvement in symptoms and overall severity and…
Reaction time (“mental set”) in control and chronic schizophrenic subjects and in postaddicts under placebo, LSD-25, morphine, pentobarbital and amphetamine
1. Auditory-manual reaction times, 2, 3.5, 5, 10 and 20 sec after flashing of a “warning” light, both on “irregular” and “regular” schedules of preparatory intervals, were measured under “no medication” conditions in 10 personnel control and 13 chronic schizophrenic subjects, as well as in “postaddicts” after administration of placebo, LSD-25, morphine, pentobarbital or amphetamine. 2. Each subject was tested twice under each condition (no medic…
Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
May 28, 2025 19:43 ET | Source: Nxera Pharma Tokyo, Japan and Cambridge, UK, 29 May 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) notes that Neurocrine Biosciences, Inc. announced that it had presented new positive data from the Phase 2 study of NBI-1117568 in adults with schizophrenia at the American […]
Coverage Details
Bias Distribution
- 75% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
